TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - SANZ GROUPAR Share Price

Certificat

DE000SU1P9H2

Delayed Deutsche Boerse AG 12:15:06 27/06/2024 pm IST
0.86 EUR -2.27% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - SANZ GROUPAR
Current month+2.33%
1 month+3.53%
Date Price Change
27/24/27 0.86 -2.27%
26/24/26 0.88 -1.12%
25/24/25 0.89 -1.11%
24/24/24 0.9 -5.26%
21/24/21 0.95 -2.06%

Delayed Quote Deutsche Boerse AG

Last update June 27, 2024 at 12:15 pm IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying SANDOZ GROUP AG
IssuerLogo Issuer Société Générale Société Générale
WKN SU1P9H
ISINDE000SU1P9H2
Date issued 06/11/2023
Strike 23.82 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 0.23
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.98
Lowest since issue 0.16
Spread 0.06
Spread %6.52%

Company Profile

Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
Sector
-
More about the company

Ratings for Sandoz Group AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Sandoz Group AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
35.96 USD
Average target price
40.41 USD
Spread / Average Target
+12.37%
Consensus